Takahashi M, Ohtani S, Nagai SE, Takashima S, et al. The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a
first-line therapy in Japanese patients with inoperable or recurrent
HER2-positive breast cancer: the COMACHI study. Breast Cancer Res Treat 2020 Sep 13. pii: 10.1007/s10549-020-05921.
PMID: 32920732